SAN DIEGO – As gene therapy advances in the eye and hematopoietic stem cells, researchers are going after the harder-to-treat diseases of the central nervous system (CNS). At the Neurosciences 2018 conference, preclinical data showed the right vector and delivery technique can improve symptoms in mouse models of amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD) and Batten disease as the treatments advance to the clinic.